Ocrevus® (ocrelizumab) is an FDA-approved treatment for adults with relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. It is a monoclonal antibody designed to selectively target CD20-positive B cells, a type of immune cell believed to play a key role in the inflammation and nerve damage associated with MS. By reducing the activity of these cells, Ocrevus helps slow disease progression, reduce relapses, and limit new brain lesions. Treatment is administered by intravenous infusion at scheduled intervals, with monitoring by a healthcare provider to ensure safety and effectiveness.